MedTrace Logo

A Trial of GC4419 in Patients With Critical Illness Due to COVID-19

NCT04555096 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-03-18

Study results available
· View outcomes & findings →

Summary

A Trial of GC4419 in Patients with Critical Illness due to COVID-19

Conditions

Interventions

DRUG

GC4419

180 Minute IV Infusion

DRUG

Placebo

180 Minute IV Infusion

Sponsors & Collaborators

  • Galera Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Jon Holmlund, MD · Study Chair

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-09
Primary Completion
2021-05-28
Completion
2021-05-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04555096 on ClinicalTrials.gov